Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation.
about
Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1Diabetic cardiovascular disease: getting to the heart of the matter.In vivo administration of BL-3050: highly stable engineered PON1-HDL complexesOxidative risk for atherothrombotic cardiovascular disease.Paraoxonase-1 gene Q192R and L55M polymorphisms and risk of cardiovascular disease in Egyptian patients with type 2 diabetes mellitusType I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice.ApoA-1 in diabetes: damaged goods.Novel associations of nonstructural Loci with paraoxonase activityDialysis Modalities and HDL Composition and FunctionParaoxonase 1 Phenotype and Mass in South Asian versus Caucasian Renal Transplant RecipientsCardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents.Effect of pomegranate juice on paraoxonase enzyme activity in patients with type 2 diabetes.Identifying children at particular risk of long-term diabetes complications.Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides.Açai (Euterpe oleracea Mart.) Upregulates Paraoxonase 1 Gene Expression and Activity with Concomitant Reduction of Hepatic Steatosis in High-Fat Diet-Fed Rats.Glycation of paraoxonase 1 by high glucose instigates endoplasmic reticulum stress to induce endothelial dysfunction in vivo.Homology modeling of human serum paraoxonase1 and its molecular interaction studies with aspirin and cefazolin.A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids.Total serum oxidant/antioxidant status and arylesterase activity in recurrent aphthous stomatitis.High prevalence of low serum paraoxonase-1 in subjects with coronary artery diseaseOxidative stress and anti-oxidative defence in patients with age-related macular degeneration.Correlation studies of plasma paraoxonase activity and uric acid concentration with AAPH-Induced erythrocyte hemolysis in hemodialysis patients.Novel serum paraoxonase activity assays are associated with coronary artery disease.Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma.Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity.Serum high-density lipoprotein cholesterol level associated with the extent of periodontal inflammation in type 1 diabetic subjects.Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study.Vitamin B6 supplementation improves oxidative stress and enhances serum paraoxonase/arylesterase activities in streptozotocin-induced diabetic rats
P2860
Q28195911-ECE7C1AA-9A2E-4E1C-8904-746ED2A01F8FQ30451529-CD49211B-D7CE-4013-8F49-76A6886231D2Q30891417-EC8D63C3-9424-4F1B-994C-CE1B59419647Q33554184-927142B6-FCA5-4AB1-93F4-5197FB950936Q34788675-4C231BD7-103F-4056-BE80-FFE5178DDF7BQ35747737-B87B90A7-39E1-49B7-88DF-69303F2B4577Q35757158-C185D8B3-B0BB-434B-A9A8-AE4C6E06AAF2Q35936649-FEEDC558-2433-4BAD-BFAE-3420CCE86088Q36003077-212B385F-B838-4099-9399-4ECA242AE36CQ36021870-C857F269-88D1-43FD-BEC9-772DBFA0206AQ36679594-637B2090-1FFE-420B-A603-0DD3F4A61B79Q36686230-2D7DDDC3-5372-485B-A28A-1DDF8B79059CQ36922322-887678AD-B936-4FD2-AF8F-EC138F5DA482Q37137150-3954E14C-273E-4876-947B-B422C3C64C60Q37239685-7226CDC9-1172-4D29-9B2C-1145A64FB34FQ37736486-B9447A33-6C3C-4749-8AF2-9AD35C0D7D6DQ38450180-81934AA4-AA04-47A8-90B5-3FD7C3C466E3Q40354805-D8744F60-42B9-414F-B2B4-82164873ED75Q42575525-77D16E7B-7D7C-409C-ADD6-5B44884C16D2Q42606120-9AA4E88D-4497-4590-B8C7-6F27595C13D5Q44584637-F494B4F0-9C3B-4600-9F6A-6BD386B87804Q44815929-895B908F-76B7-4F7D-9B44-DD355649E11EQ46093421-0926FC55-68F1-4952-B414-6D8065780AF9Q46974046-4DA046BE-8B0A-4BF2-891F-6EBB0E398E5FQ46978184-1A5D8E08-E56B-4CEB-A6E1-65E8D52F1BCFQ53838129-4DD6AAB8-6B1C-45A7-8108-05C6E967514DQ55416022-8D1DC9B1-9F90-4ABD-980E-6B1C84FBB0CEQ59075555-2CA13CED-D3B8-4BE5-9DF4-7A2EAECE8568
P2860
Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Serum paraoxonase is reduced i ...... to protect LDL from oxidation.
@ast
Serum paraoxonase is reduced i ...... to protect LDL from oxidation.
@en
type
label
Serum paraoxonase is reduced i ...... to protect LDL from oxidation.
@ast
Serum paraoxonase is reduced i ...... to protect LDL from oxidation.
@en
prefLabel
Serum paraoxonase is reduced i ...... to protect LDL from oxidation.
@ast
Serum paraoxonase is reduced i ...... to protect LDL from oxidation.
@en
P2093
P1433
P1476
Serum paraoxonase is reduced i ...... to protect LDL from oxidation.
@en
P2093
P304
P356
10.1016/S0021-9150(00)00556-6
P577
2001-03-01T00:00:00Z